Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1953 2
1954 3
1955 3
1956 1
1957 3
1958 3
1959 2
1963 1
1965 5
1966 2
1967 4
1968 4
1969 7
1970 4
1971 2
1972 10
1973 10
1974 10
1975 26
1976 27
1977 34
1978 32
1979 44
1980 62
1981 58
1982 65
1983 55
1984 53
1985 87
1986 87
1987 70
1988 77
1989 70
1990 84
1991 102
1992 81
1993 119
1994 125
1995 142
1996 148
1997 169
1998 151
1999 203
2000 174
2001 204
2002 225
2003 284
2004 272
2005 346
2006 356
2007 409
2008 421
2009 442
2010 446
2011 448
2012 490
2013 534
2014 505
2015 543
2016 543
2017 602
2018 617
2019 645
2020 682
2021 666
2022 570
2023 544
2024 172

Text availability

Article attribute

Article type

Publication date

Search Results

11,861 results

Results by year

Filters applied: . Clear all
Page 1
Avacopan for the Treatment of ANCA-Associated Vasculitis.
Jayne DRW, Merkel PA, Schall TJ, Bekker P; ADVOCATE Study Group. Jayne DRW, et al. N Engl J Med. 2021 Feb 18;384(7):599-609. doi: 10.1056/NEJMoa2023386. N Engl J Med. 2021. PMID: 33596356 Clinical Trial.
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. METHODS: In this randomized, controlled trial, we assigned patients with ANCA-associated vasculitis …
BACKGROUND: The C5a receptor inhibitor avacopan is being studied for the treatment of antineutrophil cytoplasmic antibody (ANCA)-associated …
Vasculitis therapy refines vasculitis mechanistic classification.
Torp CK, Brüner M, Keller KK, Brouwer E, Hauge EM, McGonagle D, Kragstrup TW. Torp CK, et al. Autoimmun Rev. 2021 Jun;20(6):102829. doi: 10.1016/j.autrev.2021.102829. Epub 2021 Apr 16. Autoimmun Rev. 2021. PMID: 33872767 Free article. Review.
In recent years, several drugs with well-characterized immunological targets have been tested in clinical trials in large vessel vasculitis and small vessel vasculitis. ...Therefore, the aim of this systematic literature review was to examine the evidence bas …
In recent years, several drugs with well-characterized immunological targets have been tested in clinical trials in large vessel v …
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis.
Wechsler ME, Akuthota P, Jayne D, Khoury P, Klion A, Langford CA, Merkel PA, Moosig F, Specks U, Cid MC, Luqmani R, Brown J, Mallett S, Philipson R, Yancey SW, Steinfeld J, Weller PF, Gleich GJ; EGPA Mepolizumab Study Team. Wechsler ME, et al. N Engl J Med. 2017 May 18;376(20):1921-1932. doi: 10.1056/NEJMoa1702079. N Engl J Med. 2017. PMID: 28514601 Free PMC article. Clinical Trial.
METHODS: In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or refractory eosinophilic granulomatosis with polyangiitis who had received treatment for at least 4 weeks and were taking a stable prednisol …
METHODS: In this multicenter, double-blind, parallel-group, phase 3 trial, we randomly assigned participants with relapsing or …
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Turkiewicz A, Tchao NK, Webber L, Ding L, Sejismundo LP, Mieras K, Weitzenkamp D, Ikle D, Seyfert-Margolis V, Mueller M, Brunetta P, Allen NB, Fervenza FC, Geetha D, Keogh KA, Kissin EY, Monach PA, Peikert T, Stegeman C, Ytterberg SR, Specks U; RAVE-ITN Research Group. Stone JH, et al. N Engl J Med. 2010 Jul 15;363(3):221-32. doi: 10.1056/NEJMoa0909905. N Engl J Med. 2010. PMID: 20647199 Free PMC article. Clinical Trial.
BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis for 40 years. Uncontrolled studies suggest that rituximab is effective and may be safer tha …
BACKGROUND: Cyclophosphamide and glucocorticoids have been the cornerstone of remission-induction therapy for severe antineutrophil cytoplas …
Management of cutaneous vasculitis.
Micheletti RG, Pagnoux C. Micheletti RG, et al. Presse Med. 2020 Oct;49(3):104033. doi: 10.1016/j.lpm.2020.104033. Epub 2020 Jul 6. Presse Med. 2020. PMID: 32645416 Review.
Cutaneous vasculitis encompasses cutaneous components of systemic vasculitides, skin-limited variants of systemic vasculitides, such as IgA vasculitis or cutaneous polyarteritis nodosa, and single-organ cutaneous vasculitis, as individualized in 2012 in the C …
Cutaneous vasculitis encompasses cutaneous components of systemic vasculitides, skin-limited variants of systemic vasculitides, such …
Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group. Jones RB, et al. N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169. N Engl J Med. 2010. PMID: 20647198 Free article. Clinical Trial.
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be safer than cyclophosphamide regimens. METHODS: We compared rituximab with cyclophosphamide as induction therapy in ANCA-associated vascu …
Treatment with rituximab has led to remission rates of 80 to 90% among patients with refractory ANCA-associated vasculitis and may be …
Management of inflammatory neurologic and psychiatric manifestations of systemic lupus erythematosus: A systematic review.
Papachristos DA, Oon S, Hanly JG, Nikpour M. Papachristos DA, et al. Semin Arthritis Rheum. 2021 Feb;51(1):49-71. doi: 10.1016/j.semarthrit.2020.12.004. Epub 2020 Dec 17. Semin Arthritis Rheum. 2021. PMID: 33360230 Review.
RESULTS: There were 7222 studies identified in the search, of which 90 were included in the review. There was a notable paucity of clinical trials, with only two randomised controlled trials and one pilot study. ...CONCLUSION: There are multiple therapeutic options …
RESULTS: There were 7222 studies identified in the search, of which 90 were included in the review. There was a notable paucity of clinic …
Effect of Reduced-Dose vs High-Dose Glucocorticoids Added to Rituximab on Remission Induction in ANCA-Associated Vasculitis: A Randomized Clinical Trial.
Furuta S, Nakagomi D, Kobayashi Y, Hiraguri M, Sugiyama T, Amano K, Umibe T, Kono H, Kurasawa K, Kita Y, Matsumura R, Kaneko Y, Ninagawa K, Hiromura K, Kagami SI, Inaba Y, Hanaoka H, Ikeda K, Nakajima H; LoVAS Collaborators. Furuta S, et al. JAMA. 2021 Jun 1;325(21):2178-2187. doi: 10.1001/jama.2021.6615. JAMA. 2021. PMID: 34061144 Free PMC article. Clinical Trial.
OBJECTIVE: To compare efficacy and adverse events between a reduced-dose glucocorticoid plus rituximab regimen and the standard high-dose glucocorticoid plus rituximab regimen in remission induction of ANCA-associated vasculitis. DESIGN, SETTING, AND PARTICIPANTS: This was …
OBJECTIVE: To compare efficacy and adverse events between a reduced-dose glucocorticoid plus rituximab regimen and the standard high-dose gl …
Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis.
Jayne DRW, Bruchfeld AN, Harper L, Schaier M, Venning MC, Hamilton P, Burst V, Grundmann F, Jadoul M, Szombati I, Tesař V, Segelmark M, Potarca A, Schall TJ, Bekker P; CLEAR Study Group. Jayne DRW, et al. J Am Soc Nephrol. 2017 Sep;28(9):2756-2767. doi: 10.1681/ASN.2016111179. Epub 2017 Apr 11. J Am Soc Nephrol. 2017. PMID: 28400446 Free PMC article. Clinical Trial.
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment contribute to the morbidity and mortality of vasculitis. We determined whether avacopan (CCX168), an orally administered, selective C5a …
Alternative C activation is involved in the pathogenesis of ANCA-associated vasculitis. However, glucocorticoids used as treatment co …
Vasculitis in children.
Eleftheriou D, Batu ED, Ozen S, Brogan PA. Eleftheriou D, et al. Nephrol Dial Transplant. 2015 Apr;30 Suppl 1:i94-103. doi: 10.1093/ndt/gfu393. Epub 2014 Dec 30. Nephrol Dial Transplant. 2015. PMID: 25550447 Review.
We provide an overview of paediatric vasculitides with emphasis on key differences in vasculitis presentation and management between children and adults. Significant advances in the field of paediatric vasculitis research include the development of classification cr …
We provide an overview of paediatric vasculitides with emphasis on key differences in vasculitis presentation and management between …
11,861 results
You have reached the last available page of results. Please see the User Guide for more information.